Strapped For Cash GenSight Eyes Survival Options
French Firm Pulls Lumevoq Filing
Executive Summary
The future of GenSight hangs in the balance following the decision to withdraw its application in Europe for Lumevoq, the company's gene therapy for Leber hereditary optic neuropathy, and worries over a rapidly diminishing cash pile.
You may also be interested in...
EMA Decision Time For GSK’s RSV Older Adult Vaccine & Roche’s Glofitamab For LBCL
A number of companies could soon find out whether the European Medicines Agency will back pan-EU marketing approval for their respective products.
Partner Or Go It Alone? TG Therapeutics Ponders EU Plans For Briumvi
TG Therapeutics has successfully launched Briumvi on its own in the US, despite fierce competition from established same-class MS drugs Ocrevus and Kesimpta, but is still weighing up the pros and cons of partnering for the European market.
Cosentyx Becomes First Biologic Approved For HS In Nearly A Decade
The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.